Instructions Cardonat capsules container No. 20
Composition
active ingredients: cobamamide (dibencoside, coenzyme B12), cocarboxylase (chloride) (coenzyme B1), pyridoxal-5-phosphate (coenzyme B6), carnitine chloride, lysine hydrochloride;
1 capsule contains cobamamide (dibencoside, coenzyme B12) – 1 mg, cocarboxylase (chloride) (coenzyme B1) – 50 mg, pyridoxal-5-phosphate (coenzyme B6) – 50 mg; carnitine chloride – 100 mg, lysine hydrochloride – 50 mg;
excipients: talc, colloidal anhydrous silicon dioxide;
capsule composition:
cover: gelatin, titanium dioxide (E 171), ponceau 4R (E 124), sunset yellow FCF (E 110);
shell: gelatin, titanium dioxide (E 171).
Dosage form
Capsules.
Main physicochemical properties: hard gelatin capsules No. 1 or No. 2 with a white or orange body and an orange or red cap. The contents of the capsules are a powder from whitish-yellow to light orange with dark and/or white inclusions.
Pharmacotherapeutic group
Vitamins in combination with various substances. ATX code A11J C.
Pharmacological properties
Pharmacodynamics
Cardonate is a combined drug, the action of which is due to the synergistic effects of the components included in its composition. L-carnitine is a trimethylammonium (betaine) derivative of g‑amino-b-hydroxybutyric acid, belongs to the drugs with anabolic action. It is synthesized in the liver, kidneys and central nervous system from the amino acids lysine and methionine with the participation of iron and ascorbic acid, in the blood plasma it is present in free form and in the form of acylcarnitine esters. Carnitine is the main cofactor and regulator of fatty acid metabolism in the myocardium, liver and skeletal muscles, the only carrier of long-chain fatty acids in the mitochondria, where their beta-oxidation to acetyl-CoA occurs, which is a substrate for the formation of ATP in the Krebs cycle. It promotes the release of metabolites and toxic substances from the cytoplasm, improves metabolic processes. Under normal oxygen supply conditions, it shifts cell metabolism to the oxidation of fatty acids as the most energy-intensive substrate, and under hypoxia conditions, L-carnitine removes toxic metabolites of fatty acids from mitochondria, shifting cell metabolism to glucose oxidation, thus exerting an antihypoxic effect. Increases performance, accelerates growth, causes an increase in muscle mass and a decrease in adipose tissue mass due to lipolytic action, reduces the peripheral effect of thyroid hormones, contributes to the normalization of basal metabolism in hyperthyroidism. Reduces symptoms of physical and mental fatigue, exhibits neuro-, hepato- and cardioprotective effects, exhibits anti-ischemic effects, contributes to the limitation of the infarct zone, improves the processes of nerve impulse transmission in synapses and axons by increasing the synthesis of choline and acetylcholine, glutamic acid, reduces the concentration of ammonia in nervous tissue, stimulates cellular immunity. Eliminates functional disorders of the nervous system in patients with chronic intoxications, including alcoholic intoxication, alleviates the course of withdrawal syndrome, inhibits dystrophic changes in the retina. Carnitine exhibits an antiketogenic effect, reducing the production of ketone bodies from higher fatty acids.
Lysine is an essential amino acid that participates in all processes of assimilation and growth, promotes ossification and growth of bone tissue, stimulates cell mitosis, improves oogenesis and spermatogenesis, and has a direct antiviral effect on herpes simplex viruses.
Vitamin B12 coenzyme (cobamamide) has anabolic activity, activates the metabolism of carbohydrates, proteins and lipids, participates in the synthesis of labile methyl groups, in the formation of choline, methionine, nucleic acids, creatine, promotes the accumulation of compounds with sulfhydryl groups in erythrocytes. As a growth factor, it stimulates bone marrow function, which is necessary for normoblastic erythropoiesis. Cobamamide helps to normalize liver and nervous system dysfunctions, has an antiketogenic effect, activates the blood coagulation system, in high doses causes an increase in the activity of thromboplastin and prothrombin.
Vitamin B1 coenzyme (cocarboxylase) exerts a regulatory effect on metabolic processes in the body. It plays a particularly important role in carbohydrate and fat metabolism, primarily in the oxidative decarboxylation of ketoacids (pyruvic, a-ketoglutaric), as well as in the pentose phosphate pathway of glucose breakdown. It reduces the level of lactic and pyruvic acid in the body, improves glucose absorption, trophism of nervous tissue, and has a cardioprotective effect.
Vitamin B6 coenzyme (pyridoxal-5-phosphate) plays an important role in metabolism, necessary for the normal functioning of the central and peripheral nervous system. It is a coenzyme of a large number of enzymes that act on non-oxidative amino acid metabolism (decarboxylation, reamination processes). It participates in the metabolism of tryptophan, methionine, cysteine, glutamic and other amino acids. It is of great importance for histamine metabolism as a coenzyme of histaminease, contributes to the normalization of lipid metabolism, increases the amount of glycogen in the liver, improves its detoxifying properties. Catabolizes neuromuscular processes, which are especially important in childhood with delayed mental and physical development, chronic fatigue and asthenia.
Pharmacokinetics
Didn't study.
Indication
In adults and children: physical and mental overstrain, including in athletes, decreased performance, asthenic syndrome, vegetative-vascular dystonia, during the period of convalescence after somatic and infectious diseases, as well as surgical interventions, acetonemic syndromes of various genesis, liver diseases (hepatitis, cirrhosis), metabolic cardiopathies, chronic heart failure (as part of complex therapy), to improve ossification in the complex therapy of osteoporosis and bone fractures.
In children: lag in mental and physical development (hypotrophy, anorexia, growth retardation).
In adults: peripheral neuritis, neuralgia, radiculopathy, as part of complex therapy of acute and chronic cerebral circulatory disorders (cerebral strokes and chronic cerebral ischemia), as part of complex therapy of ischemic heart disease (angina pectoris, myocardial infarction), hyperhomocysteinemia, as part of complex therapy of alcohol dependence syndrome, including during withdrawal, hyperthyroidism.
In obstetric and gynecological practice: gestosis of pregnant women, fetoplacental insufficiency and intrauterine growth retardation.
Contraindication
Hypersensitivity to the components of the drug, malignant neoplasms, peptic ulcer of the stomach or duodenum in the active phase.
Interaction with other medicinal products and other types of interactions
When used simultaneously with levodopa, its therapeutic activity may be reduced due to interaction with pyridoxal. Cardonate may potentiate the effects of antihypertensive agents, cardiac glycosides, peripheral vasodilators, insulin and other hypoglycemic agents.
Application features
Do not exceed the recommended doses of the drug.
Ability to influence reaction speed when driving vehicles or other mechanisms
No effect.
Use during pregnancy or breastfeeding
The drug should be used by pregnant women only as directed and under the close supervision of a doctor. It is not known whether the active ingredients of the drug penetrate into breast milk, therefore, Cardonat can be used during breastfeeding when the potential benefit to the mother outweighs the potential risk of side effects in the child.
Method of administration and doses
Adults and children over 15 years of age should take Cardonat 1-2 capsules 3 times a day after meals. Children 5-15 years of age should take 1 capsule 2 times a day. Children 1 to 5 years of age are recommended to take the contents of 1 capsule once a day. When used in children 1 to 5 years of age, the contents of the capsule should be pre-dissolved in 50-100 ml of any fruit juice or sweet water.
Dose adjustment is not required for the treatment of pregnant women.
For anorexia, the drug should be used 15-20 minutes before meals.
If you have difficulty swallowing the capsule (children, patients in the postoperative period, people who have had a stroke), you can dissolve the capsule contents in juice or sweet water before taking it.
The average duration of the treatment course is from 3 weeks to 3 months.
Children
Use for children over 1 year of age.
Overdose
Tachycardia, dyspeptic disorders, agitation, increased or decreased blood pressure may occur, which disappear after discontinuation of the drug and do not require therapeutic measures.
Adverse reactions
The drug is usually well tolerated, but occasionally, as a rule, with individual hypersensitivity, allergic reactions may occur, including various skin rashes, itching, urticaria, angioedema. In this case, treatment should be discontinued and a doctor should be consulted.
On the part of the gastrointestinal tract: possible abdominal bloating, pain in the epigastric region, heartburn, nausea, vomiting, bowel disorders.
From the cardiovascular system: possible rapid heartbeat, changes in blood pressure.
From the side of the central nervous system: very rarely, excitation occurs.
The capsule shell contains sunset yellow FCF (E 110) and ponso 4R (E 124), which may cause allergic reactions.
Expiration date
2 years.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
20 capsules in a plastic container and a cardboard pack.
Vacation category
Without a prescription.
Producer
Joint Ukrainian-Spanish enterprise "Sperco Ukraine".
Location of the manufacturer and its business address
21027, Ukraine, Vinnytsia, 600-anniversary St., 25.
